QualityDipStocks / Health Care · Pharmaceuticals
Nektar Therapeutics NKTR
Outside our quality screen, so we don’t track its dips. It’s 63% below its 52-week high.
Outside our quality screen, 32% under its Market Value. No fair value estimate for now: its free cash flow is negative.
- Fair value est.
- n/a
- Market Value
- $54.49price −32%
- Off 52-wk high
- −63%
- Risk vs market
- Market-likebeta 1.03
52-week range 3% of the way from its 52-week low to its high
Price $36.95Market Value $54.49
4 bullish · 5 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for NKTR: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much NKTR moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves about in line with the market, and its own price swings are 6.6× the S&P 500’s.
- Beta vs S&P 500
- 1.03
- Volatility
- 85% vs 13% SPY
- Correlation SPY
- 0.16
- Correlation QQQ
- 0.13
How it ranks
Where NKTR stands vs every one of the 2,467 stocks we cover that has the number. Longer bar = better.
Not in the top quarter on any of these 3 measures
- Free cash flow yield−18% · free cash flow vs market capLowest 1%of 1,690
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 2,227
- Revenue growth, last 12 months−27% · vs the 12 months beforeLowest 1%of 2,184
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $54.49
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
ProfitabilityGross margin widened to 100.0% in FY2025 from 62.5% in FY2023 (SEC filings).
ProfitabilityOperating margin widened to −106.9% in FY2024 from −145.8% in FY2023 (SEC filings).
ValuationPrice / book of 1.4×, below the 4.8× median for the 291 Health Care companies we cover.
ValuationTrades 32.2% below its Market Value of $54.49, the average price paid since the Aug 13 filing.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$234M over the last 12 months), so there’s no cash-flow value under the price.
GrowthSales fell 27% over the last 12 months vs the 12 months before (SEC filings).
ProfitabilityLost $157M over the last 12 months (net income, SEC filings).
GrowthSales shrank 16% a year from FY2022 to FY2025.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%; sales down vs the year-ago quarter.
All fundamentals
FCF yield -18.0% · ROE -36% · Sales −27%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −18.0%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 23.81×
- Price / book
- 1.44×
- Market cap
- $1.3Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $55M
- Sales growth, 12 months
- −27.2%vs the 12 months before
- Sales growth, 3 yrs
- −15.7%/yrfrom FY2022
- Diluted EPS, 12 months
- −$6.12
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$157M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- n/an/m
- Net margin
- n/an/m
- FCF margin
- n/an/m: revenue near zero
- Return on equity
- −36%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $684M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- −$234M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- n/ano quarterly diluted share count
- Stock-based comp
- $12M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Nektar Therapeutics ’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.2B · Sales −9%
- Free cash flow, 12 months−$0.2B
- Free-cash-flow yield-18.0%
- Gross margin100%
- Operating marginn/m
- Return on invested capital−50%
- Return on equity−36%
- Sales growth (latest quarter vs year-ago quarter)−9%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $36.95
- 52-wk lowlowest close, 1 year$35.12−5.0%
- PriceMon Nov 2 close$36.95you are here
- Market Valueavg paid since Aug 13$54.49+47.5%
- 52-wk highhighest close, 1 year$100.35+171.6%
Momentum & 52-week range
RSI 31 · 5 days −1.3%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 12
- DateThu Nov 12, after the close
- Consensus EPS($2.16)
- Year-ago EPS($1.85)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
NKTR is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Nektar Therapeutics in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.